Mon, Sep 22, 2014, 3:12 PM EDT - U.S. Markets close in 48 mins.


% | $
Quotes you view appear here for quick access.

Oculus Innovative Sciences, Inc. Message Board

carylindsay1443 8 posts  |  Last Activity: Aug 21, 2014 9:13 AM Member since: Apr 18, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by carylindsay1443 Aug 21, 2014 9:13 AM Flag

    The Baxter news today is a positive going forward, also, one might head over to the NKTR website and look under the Media Highlights Section for a very positive article--Drug Discovery News. This article gives details about brain cancer drug. Article was issued in July, but some might not have seen it.

    Sentiment: Strong Buy

  • by carylindsay1443 Aug 18, 2014 6:30 PM Flag

    Finally OCLS has admitted that they have no patent on their bleach water snake oil product--all this clamoring about their patented 'product' is put to rest. Read carefully what they admit and tried to bury in their latest Q report.

    "In April 2014, Innovacyn notified us that over the next twelve months, Innovacyn intends to transition to a new supplier of product which is currently supplied by us both for animal health care and OTC wound care. We are discussing a transition agreement with Innovacyn that could potentially offset the elimination of any Innovacyn-generated revenue. We are actively seeking new distribution channels and locating a new animal health care partner. "

    What has been their biggest source of revenue---animal care--and their biggest marketing arm is 'transitioning' to a new supplier of the bleach water----so what this is saying--anyone can make the product and OCLS has no recourse against them because you can't patent Clorox bleach.

  • Reply to

    Yet another "gentle price decrease"

    by eastmoorbartender Aug 12, 2014 5:00 PM carylindsay1443 Aug 17, 2014 5:49 PM Flag

    Sure---Deerfield is upset, CEO is inept in boosting shareholder value! Stock is up about 290% from 52 week low..........cry me a river! I'm sure that you have nearly 300% winners in all your other holdings. Why are you bothering to hold FLML?

    Sentiment: Strong Buy

  • by carylindsay1443 Aug 1, 2014 11:03 AM Flag

    The current issue(Sept) of Consumer Reports has a front page cover story about--"America's Scary Pain Pill Habit"---Our use of these meds is skyrocketing--and so are overdoses. Can the FDA do more to protect us?"

  • by carylindsay1443 Jul 28, 2014 9:39 AM Flag

    Jefferies analyst David Steinberg reiterated a Buy rating and $15 price target on Nektar Therapeutics (NASDAQ: NKTR) following investor meetings with Nektar management.
    Steinberg comments, "We increasingly believe NKTR shares offer a favorable risk/reward profile. Two important programs (BAX855, Movantik) will have critical clinical/regulatory catalysts in the next 2 months, with the latter seemingly de-risked post a recent Adcom. Fovista now looks like an underappreciated opportunity while 181 (potential $1B+ peak) may yet have life despite being written off. Few companies have a rich catalyst calendar like NKTR."

  • by carylindsay1443 Jul 16, 2014 9:10 AM Flag

    After spending time with management, Summer Street says it is incrementally positive on Flamel Technologies due to multiple potential catalysts in the second half of 2014. The firm expects Flamel's neostigmine for reversing muscle blocks, Bloxiverz, will near 100% market share by Q4 as unapproved neostigmines exit the market. It reiterates a Buy rating on the stock with a $25 price target.

  • by carylindsay1443 Jun 25, 2014 1:58 PM Flag

    Appears we've got a bleeder on our hands----can they survive until tomorrow---you know! Always tomorrow when the pot of gold is going to be found for those investing their money in this POS operation.

  • by carylindsay1443 Jun 25, 2014 10:00 AM Flag

    More promises tomorrow-----you know! Always tomorrow!

2.26-0.02(-0.88%)3:07 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.